Last reviewed · How we verify
NCT06991374
Study on the Surgical Strategy of Corneal Endothelial Protection for Hard Nuclear Cataract Patients
NA trial testing combined burst mode in Hard Nuclear Cataract in 207 participants. Completed in 1 March 2025.
25 December 2024
Quick facts
| Lead sponsor | Eye & ENT Hospital of Fudan University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 207 |
| Start date | 10 August 2022 |
| Primary completion | 25 December 2024 |
| Estimated completion | 1 March 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- combined burst mode
- torsional mode
Conditions studied
- Hard Nuclear Cataract — all drugs for Hard Nuclear Cataract →
- Phacoemulsification Cataract Surgery — all drugs for Phacoemulsification Cataract Surgery →
- Endothelial Cell Density Loss — all drugs for Endothelial Cell Density Loss →
- Central Corneal Thickness — all drugs for Central Corneal Thickness →
Sponsor
Eye & ENT Hospital of Fudan University
Who can join
Adults 50 to 95, any sex, with Hard Nuclear Cataract or Phacoemulsification Cataract Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, we compared two types of phacoemulsification commonly used in cataract surgery to evaluate their effect on the prognosis of patients with hard nuclei. This will provide a theoretical basis for selecting a more appropriate cataract surgery modality in practice in hard-nucleus patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Combined Burst Mode versus Torsional Mode Phacoemulsification for Patients with Hard Nuclear Cataracts: A Prospective Comparative Cohort Study.
Ainiwaer M, Hong Y, Xiao B, Sun Y, et al · · 2026 · PMID 41852705 · DOI 10.2147/opth.s587531
Verify or expand the search:
- PubMed search for NCT06991374
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Eye & ENT Hospital of Fudan University trials
Trials by the same sponsor.
- NCT07522879 — A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Re · Phase 2 · not yet recruiting
- NCT07563088 — SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma · not yet recruiting
- NCT07575334 — Acupuncture Therapy for Sudden Sensorineural Hearing Loss · NA · recruiting
- NCT07320508 — Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study · Phase 2 · recruiting
- NCT07315802 — New Pattern of Retinal Laser Treatment for PDR · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06991374 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eye & ENT Hospital of Fudan University
- Last refreshed: 28 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06991374.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing